Single-cell multiomics reveals activation of the STAT3-PIM1 axis in T-cell subsets in proteinase 3-ANCA-positive granulomatosis with polyangiitis [0.03%]
单细胞多组学揭示了PR3-ANCA阳性肉芽肿性血管炎中T细胞亚群STAT3-PIM1轴的激活
Nanthicha Inrueangsri,Carlo G Bonasia,Kevin P Mennega et al.
Nanthicha Inrueangsri et al.
Objectives: Granulomatosis with polyangiitis (GPA) is an autoimmune disease marked by relapses and treatment-related morbidity. CD4⁺ T cells play a central role in GPA pathogenesis, but their molecular profile remains in...
Progression from symptom onset to rheumatoid arthritis: is the trajectory similar in anticitrullinated protein antibody-positive and -negative disease? A comparative longitudinal study [0.03%]
抗环瓜氨酸肽抗体阳性与阴性类风湿关节炎的发病进程：一项纵向比较研究
Mitra Hosseini Malekroudi,Stijn Claassen,Hanna W van Steenbergen et al.
Mitra Hosseini Malekroudi et al.
Objectives: The period between symptom onset and the development of rheumatoid arthritis (RA) is a putative window for disease modification. It is insufficiently known whether anticitrullinated protein antibody (ACPA)-pos...
Correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et al [0.03%]
Mysler等关于“Upadacitinib与阿达木单抗治疗肿瘤坏死因子抑制剂疗效不足或无法耐受的类风湿关节炎患者：SELECT-SWITCH随机双盲试验的12周结果”的来信答复文章
Wenpeng Zhang,Yiwen Ding,Xiaowei Zhang et al.
Wenpeng Zhang et al.
Effect of apremilast on whole-body magnetic resonance imaging of peripheral and axial inflammation in patients with psoriatic arthritis [0.03%]
阿普利马斯特对银屑病关节炎患者外周和轴向炎症全身磁共振成像的影响
Mikkel Østergaard,Robert G W Lambert,Walter P Maksymowych et al.
Mikkel Østergaard et al.
Objectives: To describe the effect of apremilast on peripheral and axial psoriatic arthritis (PsA) manifestations as assessed by whole-body magnetic resonance imaging (WB-MRI), including the effect of apremilast on inflam...
Josef S Smolen
Josef S Smolen
International expert consensus recommendations on standardised nomenclature of SSA/Ro (TROVE2/Ro60 and TRIM21/Ro52) autoantibodies in autoimmune diseases [0.03%]
国际专家共识推荐自身免疫性疾病中SSA/Ro（TROVE2/Ro60和TRIM21/Ro52）自身抗体标准化命名的意见书
Roko P A Nikolic,Eldad Ben-Chetrit,Marvin J Fritzler et al.
Roko P A Nikolic et al.
Objectives: Autoantibodies directed against Telomerase RNA Ro y-RNAs and Vault RNAs Domain Family Member 2 (TROVE2)/Ro60 and Tripartite Motif 21 (TRIM21)/Ro52 are historically related to distinct SSA/Ro autoantigens. Howe...
Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment [0.03%]
银屑病关节炎疗效终点因基线疾病活动程度而异，但与既往肿瘤坏死因子抑制剂治疗无关
Alexis Ogdie,Philip J Mease,Emmanouil Rampakakis et al.
Alexis Ogdie et al.
Objectives: Efficacy thresholds allow interpretation of randomised clinical trials (RCTs) and establishment of treatment targets. To assess the need for more personalised treatment goals, minimal clinically important impr...
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease [0.03%]
广泛的炎症相关蛋白筛选鉴定出血清CCL19是IgG4相关性疾病活动性新的生物标志物
Federica Bonaso,Bohang Jiang,Laura J Yockey et al.
Federica Bonaso et al.
Objectives: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterised by mass-forming lesions. The smouldering tempo and often asymptomatic nature of IgG4-RD pose challenges in the monitoring of di...
Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis [0.03%]
抗PAD4抗体连接自身免疫与CTL相关类风湿性关节炎中的PAD4
Kusuma Ananth,Katharine B Moosic,Eduardo Gomez-Banuelos et al.
Kusuma Ananth et al.
Objectives: We aimed to study the serologic, genetic, and immunologic underpinnings associated with cytotoxic T lymphocytes (CTLs) in rheumatoid arthritis (RA), using T-large granular lymphocytic leukaemia with comorbid R...
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial [0.03%]
新型TYK2抑制剂德考韦奇蒂尼治疗系统性红斑狼疮患者的全血转录组谱分析及作用机制的新见解：来自PAISLEY SLE II期临床试验的事后分析结果
Edward Vital,Chun Wu,J Michelle Kahlenberg et al.
Edward Vital et al.
Objectives: To further understand the mechanism of action of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY SLE trial. ...